Join
Live feed
·
PRReleasevia Quantisnow
Humacyte Inc. logo

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

ByQuantisnow·Wall Street's wire, on your screen.
HUMA· Humacyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HUMA (Humacyte Inc.) and more on Quantisnow.